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Status epilepticus (SE) is a frequent neurological emergency . The incidence 
of SE has a bimodal distribution with peaks in children aged less than a year and 
the elderly[1].Although conventional antiepileptic drugs (AED) can terminate SE
 
in most cases, a substantial minority of patients develop medically refractory status
 epilepticus (RSE).
Status epilepticus is defined as a continuous convulsion lasting longer than 
30 minutes or the occurrence of serial convulsions between which there is no return of 
consciousness[2].  Mild  degrees  of  pure  hypoxia  causes  impaired 
judgement,inattentiveness,motor  incoordinationand  at  times,euphoria.  With  hypoxic 
ischemia, consciousness is lost within seconds. If circulation is restored 
within 3-5 minutes, full recovery may occur, but if hypoxic-ischemia lasts beyond 
3-5 minutes some degree of permanent cerebral damage is the rule[3]. Status Epilepticus 
is common in childhood, and the reported current mortality is in the
range of 4-6% [4].
The evolution of a prolonged seizure into Status Epilepticus is associated 
with increased morbidity and mortality. Hypoxia is currently thought to be responsible 
for most of the complications seen in Status Epilepticus. [5].
REFRACTORY STATUS EPILEPTICUS (RSE):
Although  the  entity  of  RSE  is  widely  recognized  and  discussed,  a  standard 
definition  has  not  yet  been  evolved  and  is  usually  defined  as  seizure  activity  that 
continues after first- and second-line therapy has failed.[6]Such patients are considered 
to be in Refractory Status Epilepticus and escalation of therapy with administration of 
barbiturate or non-barbiturate anesthetic agent is then recommended with the therapeutic 
endpoint  of  achieving  seizure  control,  electrical  silence  or  both  [7].  These  patients 
require management in pediatric intensive care unit, with continuous cardiorespiratory 
and electro-encephalographic monitoring along with the aggressive therapy to control 
seizures
The optimal management of such patients remains unclear and large, controlled 
studies  comparing  the  various  agents  are  lacking.  Generalized  status  epilepticus  is 
refractory to standard anticonvulsant therapy in at least 9% of patients and additional 
intervention is required [8 ,9].
The significant morbidity and mortality in refractory status epileptics is due to the 
nature of underlying illness and sustained seizure activity as well as the toxicity of  con-
current treatment modalities. Many studies have come out which suggest that continuous 
intravenous infusion of midazolam in safe and effective therapy for refractory status 
epilepticus. On the other hand studies using other drugs e.g. Pentobarbital,  propofol, 
ketamine  anesthesia  and  paraldehyde  were  shown  to  be  associated  with  many 
disadvantages due to their side effects.
Though refractory status epilepticus is a life threatening condition,  there is no 
standard  drug  or  standard  protocol  for  its  treatment  and  also  treatment  varies  from 
institution to institution. Many drugs are being tried and there is no fixed consensus 
arrived as which would be the best in children for early control of seizures and having 
minimal side effects. Very few studies have been done in India and abroad on Refractory 
Status Epilepticus, so, the data on the clinical profile and treatment modalities and their 
effectiveness is  also limited.  Moreover,  the drugs and the doses at  which refractory 
status epilepticus was controlled on western population may not be same in our children. 
Important causes of status epilepticus [10]: The important causes can be broadly 
divided into:







Status Epilepticus can occur  as  a  first  manifestation of  epilepsy or  during the 
course  of  epilepsy  with  or  without  an  underlying  neurological  disorder.  In  known 
epilepticus,  drug  default  or  sudden  withdrawal  of  antiepileptics  or  undercurrent 
infections and stress may predispose to status epilepticus. 
3. Degenerative or Progressive Neurological Conditions
After  a  single  episode  of  status  epilepticus,  subsequent  episodes  are  more 
common with risk of recurrence of 17% for a second episode and 5% for further attacks 
[11].  In relation to premorbid state, the recurrence risk for status epilepticus for those 
with prior neurological abnormalities is about 50% and in those who are neurologically 
normal, it is 3% [11]. 
If  status  epilepticus  could  not  be  controlled  by  front-line  anticonvulsants 
(Diazepam, lorazepam, phenytoin and phenobarbitone) and seizures become refractory 
then the following reasons should be reassessed systematically [12].
1. Adequacy of drug therapy.
2. Initiation of appropriate maintenance antiepileptic therapy
3. Failure to identify and treat the underlying causes e.g. Acutve progressive 
cerebral disorders and cerebral infections.
4. Misdiagnosis of pseudo status as status epilepticus
5. Underlying metabolic disorder or structural defects
PATHOPHYSIOLOGY OF STATUS EPILEPTICUS (SE):
 SE refers to a condition in which there is a failure of the "normal" factors 
to terminate a typical seizure. y-Aminobutyric acid (GABA) receptor-mediated 
inhibition may be responsible for the normal termination of a seizure. In addition, 
the activation of the N-methyl-D aspartate (NMDA) receptor by the excitatory 
neurotransmitter glutamate may be required for the propagation of seizure activity.[13] 
SE that is refractory to treatment may be the result of several processes and has been 
attributed  to  a  mechanistic  shift  from  inadequate  GABAergic  inhibitory  receptor-
mediated transmission to excessive NMDA excitatory receptor-mediated transmission.
[14] In  experimental  models,  resistance  to  both  benzodiazepines  and  barbiturates 
develops during prolonged seizures and it has been hypothesized that prolonged seizure 
activity  alters  the  structure  and/or  function  of  GABAA receptors.[15] SE  induced 
neuronal  death  is  morphologically  necrotic  and  is  initiated  by  excessive  glutamate 
release, which activates postsynaptic NMDA receptors and triggers receptor-mediated 
calcium influx (excitotoxicity). This results in a cascade of events and cell death.[16] 
The alterations in inhibitory and excitatory pathways have important implications 
for the pharmacological management of SE. Another important aspect of self-sustaining 
SE is the progressive,  time-dependent development  of  pharmacoresistance.  Currently 
recommended agents acts primarily through the 
GABA A receptor  and  have  been  shown  to  become  less  effective  in  SE  of  longer 
duration. Drugs shown to be effective in RSE act at different receptor sites other 
than  benzodiazepine  receptor  site,  propofol  acts  at  a  site  distinct  from  the 
benzodiazepine and barbiturate binding sites, isoflurane acts by potentiation of
inhibitory postsynaptic GABA A receptor-mediated currents, although effects on
 thalamo-cortical pathways also have been implicated.[17]
COMPLICATIONS OF STATUS AND REFRACTORY STATUS EPILEPTICUS:
Systemic changes and complications of status epilepticus and protean with the 
involvement  of  all  organ  systems  and  these  undoubtedly  contribute  to  the  ultimate 
mortality seen in patients with Status Epilepticus and Refractory Status epilepticus. As 
the duration of status epilepticus progresses, there is systemic alteration, with worsening 
of general clinical state. The final stages are characterized by respiratory compromise, 
hypotension,  hypothermia  and  ongoing  epileptiform  paroxysms  without  motor 
accompaniments. 
The table given below lists the various complications [4]:
1. Interictal coma
2. Cumulative anoxia- cerebral and systemic
3. Cardiovascular complications – Tachycardia, Bradycardia, cardiac arrest, 
hypertension, cardiac failure, shock.
4. Respiratory system failure- Apnoea, Cheyne-stokes breathing, aspiration, 
pneumonia, tachypnea, neurogenic pulmonary edema, pulmonary embolism, 
cyanosis, respiratory acidosis.
5. Renal failure- Oliguria, uremia, acute tubular necrosis, rhabdomyolysis. 
6. Autonomic disturbances – Hyperpyrexia, sweating, vomiting, hypersecretion, 
airway obstruction.
7. Metabolic and Biochemical abnormalities – Acidosis (Metabolic, lactic acidosis), 
hyper and hyponatremia, hyperkalemia, hypoglycemia, hepatic failure, 
dehydration, acute pancreatitis.
8. Infections- pulmonary, bladder
9. Others – Disseminated intravascular coagulation, multiple organ dysfunction, 
fractures, thrombophlebitis.
INVESTIGATIONS:
A battery  of  investigations  will  be  required  not  only  for  identifying  the  underlying 
etiology but also to monitor the alterations in the metabolic parameters during status 
epilepticus. The investigations for cause of status are guided by thorough history and 
clinical examination of the child. The following are the investigations, which are helpful 
in the accurate diagnosis and management of the child.
1. Complete blood counts, Blood Sugar, electrolytes, Serum calcium, 
phosphorus, magnesium levels
2. Mantoux test, resting gastric juice for acid fast bacilli toxicology screening.
3. Serum creatinine, lactate and ammonia levels.
4. Liver function tests, blood culture
5. Anticonvulsant levels, urine analysis and toxicology
6. Lumbar puncture and analysis of fluid for protein, sugar, Grams stain and 
culture
7. Arterial blood gas analysis.
8. X-ray chest, CT scan brain, MRI brain  
9. Continuous electro encephalographic monitoring.
INITIAL EVALUATION:
After  performing  a  rapid  but  thorough  cardiopulmonary  assessment  and 
stabilizing the airway, breathing and circulation, a detailed physical and neurological 
examination should be carried out to pick up the probable etiology and complications of 
seizures.
Assess  for  evidence  of  trauma;  signs  of  raised  intracranial  pressure  like 
papilloedema, bulging anterior frontenalle or focal neurological deficit; manifestations 
of sepsis or meningitis.  Look for Kussmaul breathing and dehydration suggestive of 
metabolic acidosis or irregular respirations signifying brain stem dysfunction; evidence 
of failure to thrive, a peculiar body odor or abnormal hair pigmentation that suggests an 
inborn error of metabolism and constricted or dilated pupils suggesting a toxin or drug 
as the cause of status epilepticus[2]. 
MANAGEMENT:
Prompt and aggressive management of status epilepticus is essential; because it is 
shown that there is progressive loss in the ability of antiepileptic drugs to control the 
severe  seizures  of  status  epilepticus.  This  time  dependant  development  of 
pharmacoresistant status epilepticus is extremely important in the management of status 
epilepticus [18].
The main goals of management of status epilepticus are to:
1. Support vital function
2. Terminate seizure activity as fast possible
3. Prevent recuurence of seizures
SUMMARY OF EMERGENCY MANAGEMENT OF STATUS EPILEPTICUS
Immediate
Airway         -        Protect airway – use 100% oxygen and endotracheal tube if 
necessary
Breathing - Support and use muscle relaxant if necessary
Circulation  -         Maintain adequate perfusion and normal blood pressure- support if 
necessary
Establish secure intravenous line.
Draw - Laboratory samples
Administer - 2 ml of 25% dextrose per kilogram intravenous
Anticonvulsants
First Line - Diazepam ( 0.2 mg/kg) IV
(0-10 min) (or)
Lorazepam (0.1 mg/kg) IV given over 30-60 sec. (Repeat same dose 
after 10 min. if seizures are not controlled).
Second Line- Phenytoin 20 mg/kg IV infusion
                      in 20 ml of Normal saline over 20 minutes
( Not to exceed 1 mg/kg/mt)
Seizures not controlled
Phenytoin 10mg/kg infusion half loading dose
Seizures are not controlled




MANAGEMENT OF REFRACTORY STATUS EPILEPTICUS
RSE requires more aggressive treatment and however, the optimal treatment has
 not been defined. Patients should be treated in intensive care unit, as artificial 
ventilation and hemodynamic support is required. These patients generally require 
intravenous fluids and vasopressors to treat hypotension associated with high dose 
intravenous use of anesthetic agents. In a third of adults in SE, arterial pH falls 
below 7;[19] the main contribution to this change is lactic acidosis from skeletal 
muscle,[20] which responds well to oxygen and control of convulsive activity. 
Mild acidosis might be an anticonvulsant and neuroprotective. The usual 
practice is to treat with bicarbonate if the patient is hypotensive and arterial pH if it 
is  <  7  due  to  metabolic  acidosis.  Control  of  hypothermia  is  neuroprotective.[21] 
Pharmacological treatment  
To date, no randomized controlled trials have been done for SE refractory to first- 
and second-line therapy. The most experience exists with continuous infusion 
(cIV) of pentobarbital, midazolam and propofol,[22]. The best comparative information 
comes from the systematic review by Claassen and colleagues. No difference was found 
in  mortality  among  the  groups  treated  with  cIV propofol,  cIV midazolam and  cIV 
pentobarbital. Mortality was related to patient's age and duration of SE rather than AED 
choice. A recent retrospective study investigated the effect on RSE prognosis of various 
coma-inducing  pharmacologic  options.  Mortality  and  likelihood  of  the  patient's 
condition returning to clinical baseline at discharge did not differ significantly among 
the three arms, barbiturates (pentobarbital and phenobarbital), propofol and midazolam. 
This study did not find any evidence for mortality related to propofol infusion syndrome. 
Traditionally, barbiturates such as pentobarbital or thiopental have been used to 
terminate  RSE,  inducing  coma  and  EEG  suppression.[23],[24] However  their 
effectiveness has not been studied systematically. In a systematic review of 109 adult 
patients with RSE who were treated with pentobarbital 8% experienced
acute failure; 12%, breakthrough seizures; 43%, withdrawal seizures within 48 
hours; and 8%, refractory hypotension during the therapy. EEG burst  suppression or 
complete  suppression  has  been  achieved  more  frequently  in  episodes  treated  with 
barbiturates. Pentobarbital use is also often accompanied by prolonged sedation and life 
threatening  infections.  Episodes  treated  with  barbiturates  were  associated  with 
significantly longer hospital stay for surviving patients compared with episodes in which 
barbiturates  were  not  used.
Superior pharmacokinetics and favorable adverse effect profile makes propofol the 
drug of choice. The two main advantages of propofol are a rapid onset and short 
duration of action. Propofol is a GABAA agonist that suppresses seizure activity 
via GABA-mediated inhibition of neuronal firing. Other mechanisms of action 
include inhibition of N-methyl-D aspartate receptor and modulation of calcium 
influx through slow calcium ion channels. The safety of propofol was further 
supported in recent retrospective series both in adults[22] and children. A 
prospective study has also shown its efficacy in RSE.[25] In a retrospective series 
by Rossetti et al[40] in which 27 patients who failed to intravenous clonazepam 
and phenytoin therapy were induced into burst suppression pattern on cEEG with 
cIV propofol at a dose of 2.1 to 13 mg/kg/h for 1 to 9 days while continuing 
clonazepam infusion. RSE was successfully treated with propofol in 21 (67%) 
episodes. Seven deaths (23%) wee reported and none were attributable directly to 
propofol use and no patient experienced propofol infusion syndrome. In pediatric 
RSE also propofol has been shown to be a safe and effective drug, 14 (64%) of the 
22 episodes could be adequately controlled. Two patients who were successfully 
treated with propofol died and the death was related to the underlying etiology and 
not to the use of propofol. However propofol may cause metabolic acidosis 
and cardiovascular collapse with prolonged use in children and deaths have been 
reported the propofol infusion syndrome.[26] Propofol should therefore 
be used with caution in children, ideally for short time only and the infusion rate 
should not exceed 67 ug/kg/min.[27] In a prospective study the quality of burst 
suppression was unsatisfactory in most patients. The maintenance of continuous 
burst suppression is difficult and vigilant titrating of dosage of propofol is 
necessary under EEG monitoring.[25] 
Midazolam is an effective, short acting benzodiazepine that when given as an 
infusion has an efficacy in RSE, including at sub-anesthetic doses. It has the 
advantages of rapid onset of activity and greater water solubility, avoiding the 
problem of metabolic acidosis from the propylene glycol vehicle of other 
benzodiazepines and barbiturates. Midazolam binds to GABAA receptors and 
augments GABAergic transmission, there by imparting anticonvulsant and 
sedative-hypnotic properties.[28] Duration of antiepileptic effects is minutes to 
hours. The elimination half-life is 1.5 to 3.5 hours initially. With prolonged use, 
there may be tolerance, tachyphylaxis and significant prolongation of half-life, up 
to days.[29] After 24-48 h, the dose of the drug must often be increased severalfold 
to maintain seizure control. Clinical experience with midazolam for RSE is limited. 
The reported failed treatment with midazolam ranges between 14 to 18% . [29] , [30] . 
In the series of Claassen and colleagues  acute treatment failure occurred in 18% of 
episodes, breakthrough seizures in 56%, post treatment seizures in 68% and ultimate 
treatment  failure  in  18%.  The  authors  suggest  that  titrating  continuous  intravenous 
midazolam to burst suppression, more aggressive treatment with concurrent AED or a 
longer period of initial treatment may reduce the high proportion of patients with RSE 
who relapse after midazolam is discontinued. In this series only 24% had an immediate 
and  sustained  response.
Other Pharmacological treatment:
High dose phenobarbital:
High dose of phenobarbital  with serum levels  of  100 to 200 ug/ml,  has been found 
effective and safe in the treatment of RSE in children. In another study a very high dose 
phenobarbital at accumulated daily doses up to 80 mg/kg, with a resulting serum level of 
more than 1000 mumol/l has been shown to effective in achieving seizure control in 
children  with  RSE.  In  this  study  the  adverse  effects  were  milder  compared  with 
thiopental infusion.
Ketamine:
Ketamine,  a  NMDA antagonist,  has been proved useful  in RSE[31] and it  is  also a 
neuroprotective. However, because ketamine can raise intracranial pressure, the absence 
of intracranial mass lesion should be confirmed by neuroimaging. The experience with 
this agent in RSE is very limited. 
Inhalational Anesthetics:
Inhalational  anesthesia  (IA)  is  an  alternative  approach  to  the  treatment  of  RSE.  Its 
attractive feature include efficacy, rapid onset of action and the ability to titrate the doses 
according to the effects demonstrated on the EEG.[32] Of the various agents, isoflurane 
and desflurane are the two agents that have been administrated for RSE because of their 
safety  associated  with  long-term administration.[33] In  a  recent  retrospective  study, 
seven patients with RSE were initiated to IAs (all patients to isoflurane and one patient 
in addition to desfluratne) after 1 to 103 (mean,19) days. They received multiple AEDs 
(mean 10, range 7 -15) in addition to IAs. Regardless of seizure type, isoflurane and 
desflurane  consistently  stopped  epileptic  discharges  with  adequate,  sustained 
electrographic burst suppression within minutes of initiating IA therapy. Four patients 
had  good  outcomes.  Prolonged  use  of IAs is well tolerated.[33] 
Newer AEDs:
The use of newer AEDS in the treatment of RSE has not been studied systematically. In 
6 patients with RSE unresponsive to sequential trials of multiple agents, a suspension of 
topiramate administered via nasogastric tube was effective in aborting RSE. Effective 
dosages ranged from 300 to 1,600 mg/d.[34] RSE was terminated in three children with 
topiramate loading, 5 mg/kg/day.[35] Seizure control has been achieved in patients with 
RSE by administration of levetiracetam (500-3000 mg/day) by nasogastric route.[36] 
Injectable  levetiracetam  formulation  is  available  and  the  pharmacokinetics  of 
levetiracetam administered by IV infusion was comparable across all dose groups and 
infusion rates and the pharmacokinetic profile was consistent with that for levetiracetam 
administered  orally.[37] Well  designed studies  are  needed to determine  the place  of 
newer  AEDs  as  the  use  of  drugs can avoid pharmacologic coma.  
Target of treatment-burst suppression:
Experimental  studies  demonstrated  maximal  depression  of  cerebral  metabolism with 
barbiturates with burst suppression intervals of 30 seconds.[38] Burst suppression and 
isoelectric background EEG have been shown to be accompanied by fewer recurrent 
seizures than simply stopping seizures. There is uncertainty about the optimal extent of 
EEG suppression in RSE.  Several  authors used different  burst  suppression intervals. 
Kofke et al[39] used 15 to 30 seconds as burst suppression interval. Van Ness used 3 to 
9  bursts  per  minute  during  pentobarbital  treatment.  Mirsattari  and  colleagues[33] 
considered the maintenance of burst suppression for burst duration of less than 1 second 
and suppression duration longer than 10 seconds as the goal of therapy. Where as Bleck 
advocates a more aggressive approach using isoelectric EEGs. In a recent retrospective 
study the outcome was independent of the extent of EEG burst suppression and probably 
related to the underlying cause of RSE.
Maintenance therapy:
In  parallel  with  emergency  treatment  attention  must  be  given  to  maintenance  AED 
therapy to prevent recurrence of seizures. In patients known to have epilepsy, their usual 
AEDs should be maintained and dose adjustments may be required depending on AED 
levels.  In patients presenting  denovo  the AEDs, phenytoin/fosphenytoin or valproate, 
used to control the status can in principle be continued as oral maintenance therapy. In 
others, unless relatively short-lived treatment is anticipated, the preference is to initiate 
oral maintenance therapy, valproate or carbamazepine, starting immediately at standard 
doses.[40] If additional medication is needed, the most appropriate AEDs are topiramate 
and  levetiracetam  as  these  drugs  can  be  started  at  high  doses  with  a  low  risk  of 
idiosyncratic reactions.[41]
REVIEW OF LITERATURE
A retrospective cohort ctudy was conducted by Stephen et al[42] in the
 neurological  intensive  care  unit  (NICU)  at  Columbia-Presbyterian Medical  Center 
between January 1, 1994, and March 31, 1998 to determine the frequency, risk factors, 
and impact on outcome of RSE. Consecutive sample of 83 episodes of status epilepticus 
in 74 patients were studied. In 57 episodes (69%), seizures occurred after  treatment with 
a benzodiazepine, and in 26 (31%), seizures occurred after treatment with a second-line 
anticonvulsant drug (usually phenytoin), fulfilling our criteria for RSE. Nonconvulsive 
SE (P= .03) and focal motor seizures at onset (P= .04) were identified as independent 
risk factors for RSE. Eleven (42%) of 26 patients with RSE had seizures after receiving a 
third-line agent (usually
phenobarbital). Although mortality was not increased (17% overall), RSE was associated 
with  prolonged  hospital  length  of  stay  (P<.001) and  more  frequent  functional 
deterioration at  discharge (P= .02).  They concluded that  refractory  status epilepticus 
occurs in approximately 30% of patients with SE and was associated with increased 
hospital length  of  stay  and  functional  disability.  Nonconvulsive  SE  and focal  motor 
seizures at onset were risk factors for RSE.  
M Holtkamp et al[43] retrospectively analysed all episodes of status epilepticus 
(SE) treated between 1993 and 2002 on the neurological intensive care unit (NICU) of 
the Charité-Universitätsmedizin Berlin. The predictive and prognostic features of RSE 
were compared with non-RSE (NRSE). All patients with “de novo” SE were followed 
up to identify the possible development of post-SE symptomatic epilepsy.  A total of 83 
episodes  fulfilled  their  criteria  of  SE.  Of  these  43%  were  refractory  to  first  line 
anticonvulsants. The mean age of patients with SE was 53.3 (SD 19) years, with only 
two  patients  younger  than  18  years.  Encephalitis  was  significantly  more  often  the 
primary  cause  in  RSE  (p<0.05),  whereas  low  levels  of  antiepileptic  drugs  were 
significantly more often associated with NRSE (p<0.001).  Hyponatraemia within the 
first 24 hours after onset of status activity was significantly more often associated with 
RSE (p<0.05). In RSE, compared with NRSE, significantly longer duration of seizure 
activity  (p<0.001),  more  frequent  recurrence  of  epileptic  activity  within  the  first  24 
hours after the end of seizure activity (p<0.001), longer stay in the NICU and in hospital 
(p<0.001 and p<0.01,  respectively),  and more frequent  development  of  symptomatic 
epilepsy (p<0.05) were seen. SE treated in the NICU was frequently refractory to first 
line anticonvulsant drugs. Encephalitis was a predictor for RSE, which was associated 
with markedly poor outcome, in particular, the development of post-SE symptomatic 
epilepsy.  
In a prospective study conducted by Ramon Rivera, Miguel Seginini et al [44], 24 
children diagnosed with the diagnosis of status epilepticus were admitted and treated in 
the  Intensive  Care  Unit,  National  Children’s  Hospital,  Costa  Rica  with  midazolam 
infusion. Out of 24 patients, 10 were male and 14 were female. The mean age was 2.2 
yrs (range 2 months to 12 yrs). Fourteen patients had history of epilepsy and were in 
anticonvulsants prior to admission (phenobarbital (n=6), phenobarbital plus phenytoin 
(n=4) and carbamazepine (n=4)). But at the moment of admission, the serum levels of 
these drugs are not known. The other ten patients presented at the emergency room with 
their first conclusive episode. Four patients had infection of central nervous system. Six 
had  idiopathic  epilepsy.  Majority  of  patients  (n=18)  had  generalized  tonic-clonic 
seizures,  followed  by  focal  seizures  (n=6)  and  focal  with  secondary  generalization 
(n=1). The mean time between admission to the emergency room and the establishment 
of midazolam infusion was 0.75 hrs (range 0.25 to 2.5 hrs). Complete arrest of seizures 
was achieved with midazolam therapy in all  24 patients.  The mean infusion rate of 
midazolam necessary  to  control  the  fits  was  2.3  µg/kg/min.  (range  1  to  18).  They 
observed that none of the patients experienced clinically important changes in blood 
pressure or respiratory status while receiving midazolam as an intravenous infusion. In 
addition, none of the patients required endotracheal intubation and assisted ventilation. 
The  metabolic  parameters  were  within  normal  limits  and  all  of  them regained  full 
consciousness at a mean time 4.2 hrs (range 2 to 8.5 hrs) after discontinuation of the 
midazolam infusion. They concluded that midazolam is an effective and safe therapeutic 
approach for the management of pediatric patients with status epilepticus. 
In another interesting study conducted by Roshan Lal Koul, Raj Ajithala G et al 
[45]  as  in  a  tertiary  referral  centre  in  Sultanate  of  Oman,  20  children  with  status 
epilepticus were admitted of which majority were males ( n=15) and the rest ( n=5) were 
females. The mean age was 4.07 yrs ( range 2 months to 13 yrs). Eleven children had 
history of seizures and were already taking anticonvulsants, eight children had idiopathic 
epilepsy, three had acute purulent meningitis, three had acute meningo encephalitis and 
the  remaining  had  various  vascular  or  degenerative  lesions  of  the  brain.  Majority 
presented  with  generalized  tonic  clonic  seizures  (n=13),  four  children  had  partial 
seizures,  myoclonic  status  in  one  child  and  Lennox-Gastaut  status  in  two  children. 
Twelve  patients  had  refractory  status  epilepticus.  Complete  arrest  of  seizures  was 
achieved with midazolam infusion in all but one child who had Batten’s disease. The 
mean time to control seizures in refractory status epilepticus was 64.6 minutes (range 
15-240  minutes)  and  in  established  status  epilepticus  34.3  minutes  (range  10-60 
minutes).  The mean time between start  of midazolam infusion and total cessation of 
seizures in all patients was 54 minutes. The mean infusion rate of midazolam required to 
control the seizures completely was two µg /kg/min (range 1-5 µg/kg/min). Only two 
children  had  transient  fall  in  oxygen  saturation  (to  90%)  as  demonstrated  by  pulse 
oxymetry  however,  none  of  the  patients  required  mechanical  ventilation  and  none 
showed any abnormalities in electrolyte and glucose levels. So this study too suggested 
that  midazolam infusion is  an  effective  and safe  therapeutic  approach for  refractory 
status epilepticus (RSE).
The meta-analysis conducted by Donald L. Gilbert, Peter S. Gartside [46] in 1999 
was the first study that systematically analyzed the published literature on the treatment 
of refractory generalized convulsive status epilepticus in children. One hundred eleven 
children from 12 articles published between 1983 and 1998 met their inclusion criteria. 
Five drugs (midazolam, pentobarbital, thiopental, isoflurane and diazepam) were used in 
patients  who  met  inclusion  criteria.  They  found  that  midazolam,  pentobarbital, 
thiopental and isoflurane were 100% efficacious, in an average of less than 1 hour after 
starting treatment. The only treatment failures were seen in diazepam study in which 
seizures continued in 14% of children. The efficacy of all treatments in symptomatic 
cases  was  92%  versus  96%  in  idiopathic  cases  (p=0.42).  The  overall  mortality  in 
children  treated  for  refractory  generalized  convulsive  status  epilepticus  was  16%. 
Mortality in children with symptomatic etiologies was significantly greater than that in 
idiopathic group (1 of 27; Fisher’s exact test; p=0.033). The overall mortality rate in 
children treated with diazepam was 19%; with isoflurane 40%, with pentobarbital 17% 
and with thiopental was 31%. But there were no deaths among children treated with 
midazolam.  The  incidence  of  new neurological  defects  was  25% in  the  midazolam 
studies.  With  the  apparent  effectiveness  of  midazolam  in  children  with  refractory 
generalized  convulsive  status  epilepticus,  they  suggested  that  midazolam  should  be 
considered as first line therapy for treatment of refractory status epilepticus. 
Minagawa K, Yanai s [47] reviewed 48 episodes of refractory status epilepticus in 
children. The mean age of patients was 3.5 years (range 1 month to 18 years). Nine 
children  had  epilepsy,  one  purulent  meningitis,  one  encephalitis,  one  acute  hypoxic 
ischemic encephalopathy. The types of seizure were generalized tonic clonic seizures in 
41 episodes, a tonic seizure in 3, an atypical absence in 1 and a complex partial seizure 
in 3 children. All patients were treated with midazolam infusion after a bolus dose. Forty 
one of the 48 episodes of seizures were controlled within 30 minutes after initiation of 
midazolam therapy. The mean infusion rate of midazolam required was 0.22 mg/kg/hr. 
The duration of treatment was 4.1 days. None of the patients had serious changes in the 
blood pressure or respiratory status attributable to the use of midazolam infusion. They 
concluded that midazolam infusion is an effective and safe therapeutic approach for the 
management of childhood status epilepticus.
Parent JM, Lowenstein DH in their study [48] comprising of four patients with 
refractory generalized status epilepticus, who were monitored by electroencephalogram, 
documented the cessation of seizure activity within minutes of the loading dose in all the 
patients.  No adverse  effects  occurred  during midazolam treatment.  Only  one patient 
required fluid boluses and pressure support for hypotension while the remainder of the 
patients safely tolerated midazolam despite preexisting hemodynamic instability. All the 
patients had recovered and maintained good seizure control.
In  an  Indian  study  done  by  Singhi  S,  Murthy  A et  al.,  at  Chandigarh,  they 
compared the efficacy of continuous midazolam versus diazepam infusion in RSE [49]. 
It was an open-label, randomized control study at their Intensive Care Unit. The subjects 
included 40 children,  2  to  12  years  of  age with  refractory  status  epilepticus.  Either 
continuous midazolam (n=21) or diazepam infusion (n=19) in incremental doses was 
administered for seizure control. The two groups were similar in age (mean ± SD = 4.9 
±43.6 months) and etiology. Twenty three (57.5%) of patients had acute central nervous 
system  infection.  RSE  was  controlled  in  18  (86%)  and  17  (89%)  patients  in  the 
midazolam and diazepam groups respectively (p=not significant). They found that the 
median time to control seizures was 16 minutes in both the groups, but in the midazolam 
group,  seizures  recurred  in  more  children  (57% versus  16% in diazepam group;  p< 
0.05).  The  maximum dose  (  mean  ±SD)  of  midazolam and  diazepam required  was 
5.3±2.6 µg/kg/min and 0.04±0.02 mg/kg/min, respectively. About half of the patients 
needed mechanical ventilation and 40% had hypotension in both groups but they found 
that  the  mortality  was  higher  in  the  midazolam group  (  38%)  as  compared  to  the 
diazepam group ( 10.5 %, p< 0.01>0.05). They concluded that continuous midazolam 
and diazepam infusions were equally effective for control of RSE. However, midazolam 
was associated with more seizure recurrence and higher mortality in RSE predominantly 
caused by central nervous system infections.
In a small retrospective study comprising of seven patients with refractory status 
epilepticus  done by  Kumar  A,  Bleck  TP [50],  they found that  midazolam infusions 
terminated status epilepticus in all patients in less than 100 seconds as determined by 
clinical  observation  (  three  patients)  or  electroencephalographic  monitory  (  four 
patients).  But  all  the  patients  received  mechanical  ventilation  before  receiving 
midazolam. They found that one patient developed mild hypotension. In this small study, 
they concluded that midazolam appears to be an effective and safe alternative to high 
dose barbiturate coma for the termination of status epilepticus when conventional agents 
have failed.
STUDY JUSTIFICATION
Identification of predictors for RSE is crucial for detection of patients at risk 
early in the course of the disease.Despite its frequency, little is known about the 
predictive and prognostic features of the critical condition of RSE.The clinical 
characteristics of refractory status is poorly understood and  therefore the current 
management approaches are still unsatisfactory.Refractory status epilepticus (RSE) 
is a condition in search of improved clinical characterisation and more efficient 
treatment options. In contrast with status epilepticus (SE) in general, only a few 
studies have been reported on the subgroup of refractory status and moreover there 
are very few studies of RSE in childhood.
AIMS AND OBJECTIVES
• To determine the predictors of refractory status epilepticus




Case – control study
STUDY PERIOD:
October 2007- September 2009
STUDY PLACE:
Institute of child health and hospital for children,Egmore.
STUDY POPULATION:
INCLUSION CRITERIA:                
 Continuous seizure activity lasting for more than 30 minutes or
 intermittent seizure activity without recovery of consciousness in between the 
episode in children aged between 1 month to 12 years.                
          
EXCLUSION CRITERIA:
(1) Age < 1 month
(2) Children with seizures only at home.
(3) Children with head injury
(4) Children in case group of  RSE in whom first line 
anticonvulsants were not given sequentially before starting midazolam.
CASE DEFINITION:
Cases with seizures lasting beyond treatment with a benzodiazepine and  
second line intravenous anticonvulsant drug( phenytoin and phenobarbitone ). 
CONTROL DEFINITION:
Cases with seizures responding to benzodiazepine and a second line 
intravenous anticonvulsant drug ( phenytoin or phenobarbitone).
 LIMITATION:
• Serum levels of anticonvulsants were not known during admission
• Electroencephalographic monitoring was not available
CONSENT:
                Institutional consent was obtained from the parents after explaining the 
nature of study.  
MANOEUVRE:
One hundred and eleven children between the age group of  1 month to
12  years admitted in our hospital with the diagnosis of refractory status epilepticus 
    
were included in the study group and one hundred children between the age group 
of  1 month and 12 years admitted in our hospital with status epilepticus were 
included in control group in our study.
Status epilepticus was diagnosed when child had continuous seizure lasting
 
more than 30 minutes or  several  seizures occurring without  regaining consciousness 
between the seizure activity. These children were treated with 0.1 
mg/kg of lorazepam 2 doses, 20mg/kg loading dose of phenytoin followed by 10 
mg/kg half loading dose of phenytoin and 20 mg/kg loading dose of phenobarbitone at 
predetermined time interval in succession after stabilizing the
 airway, breathing and circulation. Intubation was done prior to phenobarbitone 
administration. Refractory status epilepticus was the diagnosis if the child continued to 
have seizure activity despite adequate doses of medications mentioned above.
A thorough history was obtained from the parents regarding name, age, sex,
 area, duration of seizure prior to reaching hospital, type of seizure , presence or 
absence of fever. Past history of seizure / status epilepticus and the anticonvulsant 
drug and dose ( whether adequate ) and any history of drug default or any recent 
change in anticonvulsant drug was enquired and noted down. Any history of drug
 or toxin ingestion , family history of status epilepticus or febrile seizure was 
enquired. Presence of any neurological co morbidity and its type if present , was 
enquired in detail.
Total time taken to control the seizure , number of drugs required , whether 
ventilator support was required was noted down. The complications during status 
epilepticus and the consciousness and neurological status at the end of status 
epilepticus were recorded. Later the patients were followed up in the ward for any
 
recurrence of seizure , time taken for complete control of seizure. A thorough 
clinical examination was carried out including monitoring of vitals, oxygen  saturation 
and systemic examination to find out the cause, if any, involving the 
central nervous system, cardiovascular system, renal and respiratory system.
Complete blood count, liver function test,renal function test and chest X ray
 were done in all patients. In order to exclude electrolyte and metabolic disturbances as a 
cause or complication of seizures , blood samples were taken for
electrolytes, glucose  and calcium estimation. Mantoux, resting gastric juice for 
Acid fast bacilli, cerebrospinal fluid analysis ,cerebrospinal fluid lactate and 
pyruvate were done if indicated. Computed tomography of brain was done in all 
patients. Magnetic resonant imaging of brain was done in selected cases. Final 
diagnosis of various underlying problems was made based on the clinical history, 
physical examination and various investigation.  
The patients were further followed up for any complications acquired during 
hospital stay, duration of ventilation required length of stay in hospital stay. The 
neurological status of the child at the time of discharge was noted.
All statistical analysis (mean, median, standard deviation) was done using 




A total of 111 children in case group with refractory status epilepticus and 
100 children in control group with non refractory status epilepticus were studied.
The age distribution is as follows:
TABLE – 1
Age distribution
Age Case group Control group
< 1 yr 27(24.3%) 21( 21%)
1 – 5 yrs 28(25.2%) 23(23%)
5 – 9 yrs 24( 21.6%) 29( 29%)
9 – 12 yrs 32( 28.8%) 27(27%)
The percentage of RSE cases was comparable in all the age groups.The number of 
RSE cases in children <1 year was 27(24.3%) with an insignificant p value of 0.565 and 
Odds ratio of 1.209 . This is in contrast to the previous studies which concluded <1 year 
as a risk factor for RSE. The youngest child in the study group was 2 months and the 
child with maximum age in study group was 12 yrs. The commonest age group in this 
study was 9 – 12 yrs with 32 cases (28.8%).
The sex distribution is as follows:
TABLE- 2
SEX DISTRIBUTION
SEX CASES CONTROL TOTAL
MALE 61(55%) 57(57%) 118(55%)
FEMALE 50(45%) 43(43%) 93(45%)
The total number of male patients in the study was 118(55%), with 61 in the
 RSE group and 57 in the control group. The total number of female patients in the
 study was 93(45%), with 50 in the RSE group and 43 in the SE group. Not either
 of the sex had a significant p value and so neither were found to be a risk factor 
for RSE.
TABLE – 3
Duration of seizure prior to reaching hospital
Vast majority of the patients with RSE were brought to the hospital more 
than 60 min after onset of seizure, with the exact number being 51 in RSE group
and 30 in NRSE group with a p value of 0.015 which is significant and an odds
 ratio of  2.1 . The median duration of seizures before reaching the hospital was 40
  minutes and standard deviation was 38.12 minutes. Minimum time of seizures 
before reaching hospital was 10 minutes while the maximum time was 90 minutes.





Type of seizure Cases Control p value Odds ratio 95% confidence 
interval
Focal to GTCS 26(23.4%) 11(11%)
0.018 2.475 1.152-5.319GTCS 85(76.6%) 89(89%)
Total 111 100
Majority of the patients in both the groups had generalized tonic clonic 
seizures numbering 85 in RSE group and 89 in NRSE group. However focal to
 secondary generalization was more associated with RSE than NRSE with a Chi
 square value of 5.615 and a significant p value of 0.018 and an odds ratio of 2.475
 
with 95% confidence interval being 1.152- 5.319. This result goes hand in hand 
with the observation made by Stephan et al that focal onset of seizure was a major 
risk factor for RSE.
TABLE-5
Past history of status epilepticus






7 patients among RSE group had previous history of status epilepticus as
 against 6 in NRSE group.  Among this 7 in RSE group 2 patients had primary 
seizure disorder  and 5 were cerebral palsy children with seizures. Among this 6 in 
NRSE group 1 patient had primary seizure disorder  and 5 were cerebral palsy 
children with seizures. Past history of status epilepticus was not a risk factor for 
RSE and had an insignificant p value.
TABLE-6
Drug withdrawal











38 patients in RSE group had seizure disorder out of which 5 had primary 
seizure disorder, 20 were cerebral palsy children with secondary seizure disorder
 
and 3 were post meningitic/encephalitic sequelae with secondary seizure disorder.
7 patients in NRSE group had seizure disorder out of which 2 had primary 
seizure disorder,4 were cerebral palsy children with secondary seizure disorder 
and 1 was a post meningitic/encephalitic sequelae with secondary seizure disorder.
Drug withdrawal had a significant association with RSE with a p value of 0.001 





Case Control p value Odds ratio 95% confidence 
interval
Yes 18(47.3%) 5(19.2%)
0.031 3.78 1.82-7.42No 20(52.7%) 21(80.8%)
Total 38 26
18 patients in RSE group had a history of drug withdrawal as against 5 in
 
NRSE group. Among the 18 with history of drug withdrawal in RSE group 2 had 
primary seizure disorder,15 were cerebral palsy children with secondary seizure 
disorder and 1 was a post meningitic/encephalitic sequelae with seizure disorder. 
Among the 5 with history of drug withdrawal in NRSE group 1 had primary
 seizure disorder,3 were cerebral palsy children with secondary seizure disorder 
and 1 was a post meningitic/encephalitic sequelae with seizure disorder. History of 
drug withdrawal was  associated with RSE with a significant p value  of 0.031 .
Table-8
Recent change in AED
Recent change 









 6 patients in RSE group had a history of recent change in AED as against 3
 in NRSE group. Among the 6 with history of drug withdrawal in RSE group 2had 
primary seizure disorder,4 were cerebral palsy children with secondary seizure 
disorder and. Among the 3 with history of drug withdrawal in NRSE group 1 had 
primary seizure disorder,2were cerebral palsy children with secondary seizure 
disorder. History of recent change in AED was significantly associated with RSE
 with a p value of 0.031 .
Table-9
Neonatal seizure among children with CP
NNS among 
children with CP










19 cerebral palsy patients out of 30 in the RSE group had a prior history of
 neonatal seizure and 3 cerebral palsy patients out of 15 in the NRSE group had a 
prior history of neonatal seizure. History of neonatal seizure among cerebral palsy
children had a significant association with RSE with a p value 0.003 
 
Table-10
Shock in E- Room










All the 111 patients in RSE group had shock that was managed in
 Emergency Room with fluid boluses followed by inotropes if necessary. 85(85%)
 patients in control group had shock. 
Table -11
Recurrence of seizure after control of status epilepticus












Recurrence of seizure after control of status epilepticus was seen in 20 
patients in RSE group as against 7 in NRSE group with a p value of 0.017 and
 odds ratio of 2.92
Table-12
Ventilator support






104(93.75%) patients in RSE group required ventilator support. In the 
remaining 7 patients phenobarbitone and midazolam infusion was started in
ward and these cases were not intubated.
Table -13
Duration of ventilator support
Duration of ventilator 
support
Case Control 
<1 day 17(16.3%) 18(37.5%)
1-5 days 40(38.5%) 22(45.8%)
>5 days 47(45.2%) 8(16.7%)
Total 104 48
47 patients in RSE group required ventilator support for a longer 
period as against 8 in NRSE group. Patients in RSE group required longer
duration of ventilator support than the NRSE group.
Table -14
Complications during hospitalization
Complication Case Control 
Pneumonitis 58(52.3%) 29(29%)
Refractory shock 10(9%) 3(3%)
UTI 9(8.1%) 10(10%)
Renal failure 2(1.8%) 0(0%)
Sepsis 4(3.6%) 1(1%)
Pneumonitis  58 (52.3%) was the common complication among children 
with RSE. Refractory shock was seen in 10(9%) of RSE cases. UTI was 























Abnormal CT scan was reported in 56(51%) cases in RSE group as 
against 26(26%) in NRSE group. The association between abnormal CT findings
 and RSE is significant and has a p value of 0.001. CT scan was done in all the 
cases in both the case and control group.
Table -16
MRI changes

















MRI was done only in selected cases. Out of the 22 cases in RSE 
group MRI was abnormal in 16 cases and out of the 8 cases in control group









CNS infection 35(31.5%) 15(15%) 0.005 2.61 1.323-5.148
Seizure disorder 15(13.5%) 20(20%) 0.206 0.625 0.301-1.3
CP 30(27%) 15(15%) 0.033 2.099 1.052-4.186
Febrile seizure 10(9.7%) 40(40%) 0.0731 1.2 0.501-2.8
CVA 5(4.6%) 0 0.032 - -




2(1.8%) 1(1%) 0.0623 1.817 0.162-
20.343
Metabolic 1(0.9%) 0 0.341 - -
Neurodegenerativ
e disorder
3(2.71%) 1(1%) 365 2.75 0.281-
26.874
Toxins 3(2.7%) 0 0.098 - -
PES/PMS 5(4.6%) 7(7%) 0.434 0.621 0.192-2.041
CNS infection was the most common cause of RSE accounting for 31.5% of
 cases in the RSE group with a p value of 0.005. However CNS infection was the
 
cause in only 15% of the cases in NRSE group. CNS infection was followed by CP
 as the next common cause for RSE accounting for 27% of the cases and a 
significant p value of 0.033 . All the patients with cerebrovascular accident and
 toxin ingestion had RSE. Febrile seizure was the most common cause for NRSE 












54(48.6%) 49(49%) 0.959 0.986 0.572-1.693
Poor 
compliance
30(27%) 13(13%) 0.012 2.479 1.209-5.081
Lack of 
sleep 
4(3.6%) 3(3%) 0.807 1.209 0.264-5.537
Stress 4(3.6%) 3(3%) 0.807 1.209 0.264-5.537
   Fever was the precipitating cause for seizure in 48.6% of cases in RSE
 group and 49% of cases in NRSE group. Poor drug compliance was the 
 
precipitating factor in 27% of cases in RSE group and 13% of cases in NRSE
 
group with a significant association with RSE with a p value of 0.012 . Lack of 
sleep and stress were the precipating factor in 3.6% and 3% of patients in RSE and 











36(32.4%) 59(59%) 0.87 0.33 0.172-0.782
Recovered with 
fresh weakness
33(29.7%) 18(18%) 0.045 1.9 1.01-4.012
Recovered with 
no fresh deficit
20(18%) 11(11%) 0.3 1.93 1.04-4.013
Mortality 25(22.5%) 12(12%) 0.038 2.13 1.23-4.62
32.4% of patients with RSE recovered without any weakness and 59% of 
patients in NRSE group recovered without weakness. Fresh deficit was seen in 
29.7% of cases in RSE group compared to 18% in NRSE group. Mortality was
 higher in RSE group with 22.5% of patients succumbing to illness.
Table-20
Risk factor for refractory status epilepticus as derived by Univariate Logistic
 Regression analysis
Table- 21
Risk factors for refractory status epilepticus as derived by multiple logistic 
regression analysis
Among the  various  risk  factors  which were  analysed previously  by univariate 
analysis,  focal  onset  of  seizure  (OR(95%  C.I  )  =  2.1234  (1.012-4.239)),   drug 
withdrawal  ( OR(95% C.I ) = 8.5909 (1.574-46.88) ) , prolonged duration of seizure 
prior  to  hospitalization  (  OR(95% C.I)  =  0.012(  1.701-6.54)  )  ,  history  of  neonatal 
seizure among children with CP( OR(95% C.I ) = 13.1429 (0.8687-60.2)),  abnormal 
neuroimaging  ( OR(95% C.I ) = 4.3293 (2.0877-8.97) ), acute CNS infection ( OR(95% 
C.I  )  =  2.2368  (  1.118-4.47)  ),  were  found  to  be  the  independent  risk  factors  f  or 
refractory status epilepticus by multiple logistic regression analysis. 
DISCUSSION
This case-control study was conducted to study the risk factors for refractory 
status epilepticus and its impact on outcome of the patient.
Table-20
Comparison of age and sex distribution with other studies
Mean age Range M:F
Present study 5.91yrs 2mo-12yrs 1.06:1
Roshan la et al.,[45] 4.07yrs 2mo-13ytr 3:1
Ramon rivera et al.,[43] 2.2yrs 2mo-12yrs 1:1.4
John Igartua et al.,[51] 4.25yrs 17days-16yrs -
Minagawa K,at al.,[47] 3.5yrs 1mo-18yrs -
The mean age of children in our study was 5.91years, while in the study by 
Roshan Lal et al was 4.07  years and2.2 years in study by Ramon Rivera et al. The
 mean age was 3.5 years and 4.25 years in studies by Minagawa K et al.,and John 
Igartua et al. Less than 1 year as a risk factor for RSE as made out in the study by 
Col.M.K.Behera et al was not a risk factor in  this present study.There was no 
clustering of cases in any age group. So age was not a risk factor for refractory
 status epilepticus. The ratio of male to female in the present study was 1.06:1 
which is comparable to the study done by Ramon rivera et al ., in which it was
 
1:1.4. higher incidence in males (3 times more) was noticed in study by Roshan 
Lal et al. 
Table-21
Comparison of seizure type with other studies












GTCS 76.6% 23% 65% 755 62.55
Partial to 
GTCS
23.4% 73% 20% 4.2% 25%
Though 76.6% of the patients had GTCS in the present study, focal to 
secondary generalization was more associated with RSE with a p value of 0.018 in 
univariate analysis and a p value of 0.042 in multiple logistic regression. A 
similar observation has already been made in the study by Stephen et al.
6.3% of patients in the present study with RSE had prior history of status
 epilepticus as against 6% in the NRSE group with an insignificant p value. No
 previous studies are available to compare this as a risk factor. 
Duration of seizure prior to hospitalization was >60 minutes in 46% of 
patients in RSE group compared to 30% in NRSE group with a significant p value
 of 0.012 in multiple logistic regression . Prolonged duration of seizure prior to
 hospitalization was a risk factor for RSE , similar to the observation made by 
Ramon Rivera et al ., where the mean time was 0.75 hours.  
38 patients in the RSE group and 26 patients in NRSE group had seizure 
disorder. Drug withdrawal was a cause of RSE in 71% of the patients in RSE 
group with a significant p value of 0.001in univariate analysis and a p value of 
0,0130 in multiple logistic regression . Inadequate drug dose as a cause of RSE
 was seen in 47.3% of patients in RSE group as against 19.2% in the NRSE group 
and this as a risk factor for RSE had an insignificant p value of o.8106 in multiple 
logistic rregression .
History of neonatal seizure among children with CP was observed in 63.3%
 of RSE group compared to 20% in NRSE group with a significant p value of
 0.0009 in multiple logistic regression. This result is similar to the observation made by 
Yoko Ohtsuka et al where100% of refractory cases with CP had a history of neonatal 
seizure.
Recurrence of seizures after control of status epilepticus was seen in 18% of
 cases in RSE group as against 7% in NRSE group with a significant p value of 
0.017. A similar result of recurrence of seizure in 57% of cases of RSE was 
observed in a study conducted by Singhi S. et al.  
Ventilatory support was required in 93.7% of patients in RSE group as 
against 48% in NRSE group. 50% of patients with RSE required ventilator support
 in a study by Shinghi S et al. Most of the patients requiring ventilation in RSE 
group required it for longer duration.  
Pneumonitis was the common complication seen in 52.3% RSE patients 
followed by refractory shock (9%) and urinary tract infection (8.1%)
Abnormal neuroimaging (including CT and MRI) was seen in 63.03% of
 patients in RSE group. CT alone was abnormal in 51% of patients in RSE group as 
against 74% in NRSE group. Abnormal neuroimaging as a cause of RSE had a 
significant p value of  0001 in multiple logistic regression analysis.
CNS infection (31.5%) was the most common etiology of RSE with a 
significant p value of 0.0227 in multiple logistic regression analysis.This was followed 
by CP(27%),  however  it  had an insignificant  p  value  of  0.3266 in multiple  logistic 
regression analysis. A similar observation has been made by M. Holtkamp et al., where 
CNS infection had significant association with a p value of <0.05 . 
Children with RSE had a significantly longer duration of hospital stay and
 longer duration of stay in intensive care unit.   
Fever was the precipitating factor in 48.6% of cases in RSE and 49% of
 cases in NRSE group. Poor drug compliance was observed in 27% of cases in
 RSE group as against 13% in NRSE group. Poor drug compliance had a
 significant association with RSE with a p value of 0.012 . 
32.4% of patients in RSE group recovered normally as against 59% in NRSE 
group. 29.7% of patients in RSE group developed fresh weakness as against 18%
 in NRSE group with a significant p value of 0.045 . There was mortality in 22.5% 
of patients in RSE group as against 12% in NRSE group with a significant p value 
of 0.038 . Singhi S et al observed that there was death in 38% of cases with RSE.  
 
SUMMARY AND CONCLUSION:
In this study the following factors were found to be significantly associated with 
refractory status epilepticus
• Focal onset of seizures
• Withdrawal of antiepileptic drugs in patients with seizure disorder
• Past history of neonatal seizure among patients with cerebral palsy
• Prolonged duration of seizure prior to treatment
• Abnormal neuroimaging
• Acute CNS infection
Seizure recurrence after control of status epilepticus was more observed in 
patients with refractory status epilepticus.
Ventilator support was required for more patients with refractory status epilepticus 
and they required it for a longer period.
Pneumonitis was the most common complication seen in patients with refractory 
status epilepticus followed by refractory shock.
Most of the patients with refractory status epilepticus recovered with weakness.
Mortality was higher in patients with refractory ststus epilepticus.  
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ANNEXURE
STATUS EPILEPTICUS
                                                                                                                                        Reg
.No:
1.  Name                                                       :
2.  Age                                                          :  
                                                                                                                                            
3.  Sex                                                           :  1.  Male
                                                                        2.  Female
4.  Address                                                   :
5.  Area:                                                       :  1.  Rural
                                             
                                                                        2.  Urban
6.  Nature of ailment requiring admission   :  1.  First admission for SE
                                                                        2.  Admitted for other condition, developed 
SE later 
                                                                        3.  Known case of seizure disorder, come 
for SE
7.  Family history of SE                               :  1.  Present
                                                                        2.  Absent
8.  Family history of febrile seizure             :  1.  Present
                                                                         2.  Absent  
9.  Past history                                              :  1.  Meningitis/ Encephalitis
                                                                         2.  Neurosurgical procedure
                                                                         3.  Head injury
                                                                         4.  Known seizure
                                                                         5.  CP
                                                                         6.  CVA
                                                                         7.  Neurocutaneous syndrome
                                                                         8.  Neonatal seizure
                                                                         9.  None  
10.  Seizure history                                       :  1.  Primary SD
                                                                         2.  Secondary SD
                                                                         3.  Already had one or more SE
                                                                         4.  One episode of afebrile fits- no AED
                                                                         5.  Had simple  FS
                                                                         6.  Had atypical FS
                                                                         7.  Had febrile SE
                                                                         8.  None
11.  H/O change in seizure type during        :   1.Yes 
                                                                          2. No 
       clinical course 
12.  Past H/O AED                                       :  1.  Regular
                                                                         
                                                                         2.  Irregular
                                                                           
                                                                         3.  Not on AED
13.  Dose of AED                                          :  1.  Adequate
                                                                         2.  Inadequate
                                                                         3.  NA
14.H/O recent change in drug                        : 1.YES
                                                                          2.NO
                                                                          3.NA
15.H/O withdrawal                                         : 1.YES
                                                                          2.NO
                                                                          3.NA
          
                                                                           
16.  Type of SE                                           :  1.  GTCS
                                                                       2.  Focal simple
                                                                       3.  Non convulsive
                                                                       4.  Focal to GTCS
                                                                       5.  Myoclonic
                                                                       6.  Mixed
17.  Status epilepticus                                 :  1.  Continuous seizures
                                                                       2.  Intermittent seizures 
18.  Duration of seizure before admission :  1.  <15
      ( in minutes)
                                                                       2.  15-30
 
                                                                       3.  > 30
                                                                       4.  NA
19.  Total duration of seizure                     :  1.  < 15
       ( in minutes)                
                                                                       2.  15-30
                                                                       3.  30-60
                                                                       4.  >60
                                                                       5.  NA
20.  Emergency treatment upto                   :  1.  Benzodiazepine alone
                                                                       2.  Phenytoin loading dose
                                                                       3.  Phenytoin half loading dose
 
                                                                       4.  Phenobarbitone loading dose
                                                                       5. Midazolam infusion
                                                                        
                                                                       6.  Sodium valproate infusion
                                                                       7. Others
21.  Ventilatory support                               :  1.  Not required - improved
                                                                        2.  Not required - dead
                                                                        3.  Required- Imroved
                                                                        4.  Required – dead
22.  Type of ventilatory support                  :  1. Bag/Tube
                                                                        2.  Ventilator
23.  Complication during status                  :  1.  Physical injury
                                                                       2.  C-P arrest
                                                                       3.  Fractured bone
                                                                       4.  Shock
                                                                       5.  Respiratory depression
                                                                       6. Hyperpyrexia
                                                                       7.  Renal failure
                                                                       8.  None 
24.  Post ictal weakness                              :  1. Absent
                                                                       2.  Present-recovered
                                                                       3.  Persistent weakness
25.  After SE conscious status                    :  1.  Regained consciousness
                                                                       2.  Drousy arousable
                                                                       3.  Deeply unconscious
26.  Duration on ventilator                          :          Hrs       days
27.  Time taken to regain consciousness    :           Hrs        days
  
28.  After SE neurological status                :  1.  Normal
                                                                       2.  Deficit
                                                                       3.  No fresh deficit
29  Recurrence of seizure after SE             :  1.  Present
                                                                                
                                                                        2.  Absent
30.  No of days taken for complete             :          Days
       control of seizures                                 
                                                                          
31.  Consciousness at discharge                  :  1.  Conscious/Independent
                                                                        2.  Awake/Dependent
                                                                        3.  Drowsy arousable
                                                                        4.  Comatose
32.  Neurological status at discharge           :  1.  No deficit
                                                                        2.  Deficit
                                                                        3.  No fresh deficit
                                                                 
33.  Complications during hospitalisation   :  1.  Respiratory failure
                                                                        2.  Fever
                                                                        3.  Tachycardia
                                                                        4.  Hypotension
                                                                        5.  Pneumonia
                                                                        6.  UTI
34.  Length of stay in IMCU                       :           days
35.  Length of stay in hospital                     :           days
                                                                        
36.  Investigation                                        : 
  
1. Blood sugar level 
                          
       2.  Serum sodium level                       
       3.  Creatinine kinase level                  
       4.  Serum calcium level                      
       5.  CSF analysis
                   a.  Cell count                          
                   b.  Protein                        
                   c.  Sugar                                 
                   d.  C/S                                    
 
   
                                                             
        6.  EEG   findings                             :
        7.  CT scan                                       :  
         8.  MRI scan                                    :  
                                                                     
37.  Etiology of SE                                   :  1.  CNS infection
                                                                     2.  CVA
                                                                     3.  CP/MR
                                                                     4.  Hypoxic brain damage
                                                                     5.  Toxins
                                                                     6.  Idiopathic seizure
                                                                     7.  Neurodegenerative disorder
                                                                     8.  Neurocutaneous syndrome
                                                                     9.  Low  blood sugar
                                                                     10.  Low serum calcium
                                                                     11.  Febrile seizure
                                                                     12.  HT encephalopathy
                                                                     13. SOL
                                                                     14. PMS/PES
38.  Precipitating factors                           :  1.  Fever/ intercurrent infection
                                                                      2.  Poor compliance with AED
                                                                      3. Lack of sleep
                                                                      4.  Physical exertion
                                                                      5. TV watching
                                                                      6.  Mental stress
                                                                      7.  Others
39.  Outcome                                              :  1.  Recovered normally
                                                                       2.  Recovered with weakness
                                                                       3.  Recovered with movement disorder
                                                                       4.  Decreased cognitive function
                                                                       5.  Behavioural problem
                                                                       6.  No fresh deficit
                                                                       7.  Mortality 
  
    40. H/O neonatal seizure                           1. YES
                                                                       2.  NO      
                                                                     
                                                                           
 
 ABBREVIATIONS: 
1. RSE : Refractory Status Epilepticus
2. NRSE : Non-Refractory Status Epilepticus

